Skip to main content
Premium Trial:

Request an Annual Quote

Exact Sciences, Mayo Clinic Partner on Genetic Testing, Tumor Profiling for Cancer Patients

NEW YORK – Exact Sciences said on Thursday that it has teamed up with the Mayo Clinic to provide comprehensive genomic tumor profiling and hereditary cancer testing to cancer patients treated at Mayo.

Financial and other terms of the partnership were not disclosed.

As part of the agreement, Exact will start offering its OncoExTra comprehensive genomic profiling test, which includes DNA and RNA analysis, and its Riskguard hereditary cancer test to cancer patients at three Mayo Clinic Comprehensive Cancer Center sites in Minnesota, Arizona, and Florida, which treat more than 130,000 cancer patients each year.

The test results, which will be available to Mayo Clinic researchers and clinicians, will help guide treatment decisions, advance cancer research, and support the development of new diagnostic tests and therapies, according to the firm.

Cheryl Willman, executive director of the Mayo Clinic Comprehensive Cancer Center and a professor of cancer research, said in a statement that the genomic data will also be used to develop large language models and multimodal artificial intelligence algorithms to predict cancer risk, detect cancer early, and guide interventions. In addition, the data will be integrated into patients' health records. .

Patients will consent to have the tests performed and to share their data with the Mayo Clinic, and they will receive copies of the results for their personal records.